(HWKN) Hawkins - Overview
Exchange: NASDAQ •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US4202611095
Stock: Water Treatment, Industrial Chemicals, Health Ingredients
Total Rating 60
Risk 84
Buy Signal -0.89
| Risk 5d forecast | |
|---|---|
| Volatility | 37.9% |
| Relative Tail Risk | -8.48% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.14 |
| Alpha | 33.30 |
| Character TTM | |
|---|---|
| Beta | 0.538 |
| Beta Downside | -0.451 |
| Drawdowns 3y | |
|---|---|
| Max DD | 34.79% |
| CAGR/Max DD | 1.68 |
EPS (Earnings per Share)
Revenue
Description: HWKN Hawkins March 05, 2026
Hawkins, Inc. is a US-based company operating in the chemical sector. It focuses on water treatment and specialty ingredients.
The company has three segments: Water Treatment, Industrial, and Health and Nutrition. The Water Treatment segment provides chemicals and services for various water applications, including potable water and industrial wastewater. The Industrial segment supplies chemicals and services to diverse industries like agriculture and pharmaceuticals, manufacturing products such as sodium hypochlorite and liquid phosphates. The Health and Nutrition segment distributes and formulates ingredients for nutraceutical, functional food, and personal care products, offering items like vitamins and amino acids.
For more detailed financial analysis, consider exploring ValueRay.
Headlines to watch out for
- Water Treatment demand impacts municipal and industrial sales
- Industrial chemical prices influence segment profitability
- Health and Nutrition ingredient trends affect revenue growth
- Regulatory changes in chemical and food industries pose risks
Piotroski VR‑10 (Strict, 0-10) 7.0
| Net Income: 82.4m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.09 > 0.02 and ΔFCF/TA -2.36 > 1.0 |
| NWC/Revenue: 12.33% < 20% (prev 13.24%; Δ -0.92% < -1%) |
| CFO/TA 0.14 > 3% & CFO 137.4m > Net Income 82.4m |
| Net Debt (270.1m) to EBITDA (173.4m): 1.56 < 3 |
| Current Ratio: 2.35 > 1.5 & < 3 |
| Outstanding Shares: last quarter (20.8m) vs 12m ago -0.15% < -2% |
| Gross Margin: 22.86% > 18% (prev 0.23%; Δ 2263 % > 0.5%) |
| Asset Turnover: 126.3% > 50% (prev 134.6%; Δ -8.35% > 0%) |
| Interest Coverage Ratio: 10.27 > 6 (EBITDA TTM 173.4m / Interest Expense TTM 12.1m) |
Altman Z'' 4.62
| A: 0.13 (Total Current Assets 228.2m - Total Current Liabilities 97.2m) / Total Assets 976.5m |
| B: 0.50 (Retained Earnings 488.7m / Total Assets 976.5m) |
| C: 0.15 (EBIT TTM 123.9m / Avg Total Assets 841.9m) |
| D: 1.07 (Book Value of Equity 489.8m / Total Liabilities 457.6m) |
| Altman-Z'' Score: 4.62 = AA |
Beneish M -2.81
| DSRI: 0.99 (Receivables 123.7m/111.5m, Revenue 1.06b/952.1m) |
| GMI: 1.01 (GM 22.86% / 22.98%) |
| AQI: 1.31 (AQ_t 0.49 / AQ_t-1 0.37) |
| SGI: 1.12 (Revenue 1.06b / 952.1m) |
| TATA: -0.06 (NI 82.4m - CFO 137.4m) / TA 976.5m) |
| Beneish M-Score: -2.81 (Cap -4..+1) = A |
What is the price of HWKN shares?
As of March 09, 2026, the stock is trading at USD 148.84 with a total of 122,822 shares traded.
Over the past week, the price has changed by +1.09%, over one month by +5.92%, over three months by +8.87% and over the past year by +42.62%.
Over the past week, the price has changed by +1.09%, over one month by +5.92%, over three months by +8.87% and over the past year by +42.62%.
Is HWKN a buy, sell or hold?
Hawkins has received a consensus analysts rating of 4.00.
Therefore, it is recommended to buy HWKN.
- StrongBuy: 0
- Buy: 2
- Hold: 0
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the HWKN price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 188 | 26.3% |
| Analysts Target Price | 188 | 26.3% |
HWKN Fundamental Data Overview March 08, 2026
P/E Trailing = 37.681
P/E Forward = 33.3333
P/S = 2.9264
P/B = 6.0853
P/EG = 2.7748
Revenue TTM = 1.06b USD
EBIT TTM = 123.9m USD
EBITDA TTM = 173.4m USD
Long Term Debt = 253.4m USD (from longTermDebt, last quarter)
Short Term Debt = 9.81m USD (from shortTermDebt, last quarter)
Debt = 278.3m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 270.1m USD (from netDebt column, last quarter)
Enterprise Value = 3.38b USD (3.11b + Debt 278.3m - CCE 8.21m)
Interest Coverage Ratio = 10.27 (Ebit TTM 123.9m / Interest Expense TTM 12.1m)
EV/FCF = 38.56x (Enterprise Value 3.38b / FCF TTM 87.7m)
FCF Yield = 2.59% (FCF TTM 87.7m / Enterprise Value 3.38b)
FCF Margin = 8.25% (FCF TTM 87.7m / Revenue TTM 1.06b)
Net Margin = 7.75% (Net Income TTM 82.4m / Revenue TTM 1.06b)
Gross Margin = 22.86% ((Revenue TTM 1.06b - Cost of Revenue TTM 820.0m) / Revenue TTM)
Gross Margin QoQ = 20.82% (prev 24.12%)
Tobins Q-Ratio = 3.46 (Enterprise Value 3.38b / Total Assets 976.5m)
Interest Expense / Debt = 1.23% (Interest Expense 3.43m / Debt 278.3m)
Taxrate = 26.91% (5.27m / 19.6m)
NOPAT = 90.6m (EBIT 123.9m * (1 - 26.91%))
Current Ratio = 2.35 (Total Current Assets 228.2m / Total Current Liabilities 97.2m)
Debt / Equity = 0.54 (Debt 278.3m / totalStockholderEquity, last quarter 518.9m)
Debt / EBITDA = 1.56 (Net Debt 270.1m / EBITDA 173.4m)
Debt / FCF = 3.08 (Net Debt 270.1m / FCF TTM 87.7m)
Total Stockholder Equity = 492.7m (last 4 quarters mean from totalStockholderEquity)
RoA = 9.79% (Net Income 82.4m / Total Assets 976.5m)
RoE = 16.73% (Net Income TTM 82.4m / Total Stockholder Equity 492.7m)
RoCE = 16.61% (EBIT 123.9m / Capital Employed (Equity 492.7m + L.T.Debt 253.4m))
RoIC = 12.24% (NOPAT 90.6m / Invested Capital 739.7m)
WACC = 7.33% (E(3.11b)/V(3.39b) * Re(7.90%) + D(278.3m)/V(3.39b) * Rd(1.23%) * (1-Tc(0.27)))
Discount Rate = 7.90% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -100.0 | Cagr: -0.15%
[DCF] Terminal Value 79.34% ; FCFF base≈84.7m ; Y1≈77.3m ; Y5≈68.1m
[DCF] Fair Price = 54.15 (EV 1.40b - Net Debt 270.1m = Equity 1.13b / Shares 20.9m; r=7.33% [WACC]; 5y FCF grow -10.93% → 2.90% )
EPS Correlation: 39.89 | EPS CAGR: 8.97% | SUE: -0.32 | # QB: 0
Revenue Correlation: 50.06 | Revenue CAGR: 2.44% | SUE: -0.80 | # QB: 0
EPS next Quarter (2026-06-30): EPS=1.33 | Chg7d=-0.075 | Chg30d=-0.075 | Revisions Net=-2 | Analysts=2
EPS next Year (2027-03-31): EPS=4.17 | Chg7d=+0.000 | Chg30d=+0.000 | Revisions Net=+0 | Growth EPS=+6.9% | Growth Revenue=+6.4%
[Analyst] Revisions Ratio: -1.00 (0 Up / 2 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 5.3% (Discount Rate 7.9% - Earnings Yield 2.7%)
[Growth] Growth Spread = -1.2% (Analyst 4.1% - Implied 5.3%)
P/E Forward = 33.3333
P/S = 2.9264
P/B = 6.0853
P/EG = 2.7748
Revenue TTM = 1.06b USD
EBIT TTM = 123.9m USD
EBITDA TTM = 173.4m USD
Long Term Debt = 253.4m USD (from longTermDebt, last quarter)
Short Term Debt = 9.81m USD (from shortTermDebt, last quarter)
Debt = 278.3m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 270.1m USD (from netDebt column, last quarter)
Enterprise Value = 3.38b USD (3.11b + Debt 278.3m - CCE 8.21m)
Interest Coverage Ratio = 10.27 (Ebit TTM 123.9m / Interest Expense TTM 12.1m)
EV/FCF = 38.56x (Enterprise Value 3.38b / FCF TTM 87.7m)
FCF Yield = 2.59% (FCF TTM 87.7m / Enterprise Value 3.38b)
FCF Margin = 8.25% (FCF TTM 87.7m / Revenue TTM 1.06b)
Net Margin = 7.75% (Net Income TTM 82.4m / Revenue TTM 1.06b)
Gross Margin = 22.86% ((Revenue TTM 1.06b - Cost of Revenue TTM 820.0m) / Revenue TTM)
Gross Margin QoQ = 20.82% (prev 24.12%)
Tobins Q-Ratio = 3.46 (Enterprise Value 3.38b / Total Assets 976.5m)
Interest Expense / Debt = 1.23% (Interest Expense 3.43m / Debt 278.3m)
Taxrate = 26.91% (5.27m / 19.6m)
NOPAT = 90.6m (EBIT 123.9m * (1 - 26.91%))
Current Ratio = 2.35 (Total Current Assets 228.2m / Total Current Liabilities 97.2m)
Debt / Equity = 0.54 (Debt 278.3m / totalStockholderEquity, last quarter 518.9m)
Debt / EBITDA = 1.56 (Net Debt 270.1m / EBITDA 173.4m)
Debt / FCF = 3.08 (Net Debt 270.1m / FCF TTM 87.7m)
Total Stockholder Equity = 492.7m (last 4 quarters mean from totalStockholderEquity)
RoA = 9.79% (Net Income 82.4m / Total Assets 976.5m)
RoE = 16.73% (Net Income TTM 82.4m / Total Stockholder Equity 492.7m)
RoCE = 16.61% (EBIT 123.9m / Capital Employed (Equity 492.7m + L.T.Debt 253.4m))
RoIC = 12.24% (NOPAT 90.6m / Invested Capital 739.7m)
WACC = 7.33% (E(3.11b)/V(3.39b) * Re(7.90%) + D(278.3m)/V(3.39b) * Rd(1.23%) * (1-Tc(0.27)))
Discount Rate = 7.90% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -100.0 | Cagr: -0.15%
[DCF] Terminal Value 79.34% ; FCFF base≈84.7m ; Y1≈77.3m ; Y5≈68.1m
[DCF] Fair Price = 54.15 (EV 1.40b - Net Debt 270.1m = Equity 1.13b / Shares 20.9m; r=7.33% [WACC]; 5y FCF grow -10.93% → 2.90% )
EPS Correlation: 39.89 | EPS CAGR: 8.97% | SUE: -0.32 | # QB: 0
Revenue Correlation: 50.06 | Revenue CAGR: 2.44% | SUE: -0.80 | # QB: 0
EPS next Quarter (2026-06-30): EPS=1.33 | Chg7d=-0.075 | Chg30d=-0.075 | Revisions Net=-2 | Analysts=2
EPS next Year (2027-03-31): EPS=4.17 | Chg7d=+0.000 | Chg30d=+0.000 | Revisions Net=+0 | Growth EPS=+6.9% | Growth Revenue=+6.4%
[Analyst] Revisions Ratio: -1.00 (0 Up / 2 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 5.3% (Discount Rate 7.9% - Earnings Yield 2.7%)
[Growth] Growth Spread = -1.2% (Analyst 4.1% - Implied 5.3%)